<SEC-DOCUMENT>0000950170-23-061989.txt : 20231109
<SEC-HEADER>0000950170-23-061989.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109160229
ACCESSION NUMBER:		0000950170-23-061989
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		231392189

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>spry-20231109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-11-07T18:52:42.3590+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:spry="http://ars-pharma.com/20231109" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6ce41ec3-341a-4133-9148-9736b3fc89bb" name="dei:EntityCentralIndexKey" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066">0001671858</ix:nonNumeric><ix:nonNumeric id="F_fec97013-e028-45f1-bc64-fefbf96007cc" name="dei:AmendmentFlag" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="spry-20231109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_23ea1e35-ca75-448c-ab99-c9d712614066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-09</xbrli:startDate><xbrli:endDate>2023-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="section-group" style="margin:auto;width:6.5in;;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_164e4ecb-3525-4392-ad92-ff5d02015bd3" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7da6f05-f290-4a88-8239-ea7b8572011c" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">November 9, 2023</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af8f3e62-b507-48eb-b70a-546ae3e3ff1c" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"></td>
     <td style="width:1%;"></td>
     <td style="width:32%;"></td>
     <td style="width:1%;"></td>
     <td style="width:32%;"></td>
    </tr>
    <tr>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f7f72c2-f4f5-4064-9179-5d7563853b74" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_351af373-8aa4-4516-bd3e-6c481c791138" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39756</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_466685db-f4a3-4340-a2de-a446922ef9ba" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81-1489190</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">of incorporation)</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Commission</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.5%;"></td>
     <td style="width:1.02%;"></td>
     <td style="width:48.48%;"></td>
    </tr>
    <tr>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebb00231-8e9f-45da-89e4-48c5aa314c22" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11682 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_940a3ff8-21f2-436e-a998-040c67495f30" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 120</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b1773ab-554f-4a2c-987f-77fc832c395a" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_825e39f6-ea30-4f85-acfe-94e749952516" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c09c5d35-b152-4f78-bf76-45a0aad07bdd" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_082f02ce-61fb-47be-b9cb-9c4230b47a7e" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0796cfa9-38a6-4f1b-8308-02cd81a5c635" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">771-9307</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report.)</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.28%;"></td>
     <td style="width:96.72%;"></td>
    </tr>
    <tr style="height:11pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_2cee1272-84fd-4e5f-899d-b7bb12aa2e68" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:11pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_a5374b6f-7177-49ff-be59-bad338c87652" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:11pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_b8f2dc52-556f-4412-93e7-c8d9bfdca2ed" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:11pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_53696489-e094-40f9-95bb-c8a766776983" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"></td>
     <td style="width:1%;"></td>
     <td style="width:32%;"></td>
     <td style="width:1%;"></td>
     <td style="width:32%;"></td>
    </tr>
    <tr>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Trading</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_723adde6-a204-4baf-8fdd-ef4cb49b1f43" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4d6a0df-9de5-407e-b4e5-43dfc26c7e78" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPRY</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04282263-27c8-4bb7-b499-4dcf197b5788" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#x2013;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#x2013;2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e6db4548-af57-4f25-a393-24e8be206221" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_778c3e0a-e679-463d-b940-2e4e1867794f" contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="s88fc7c5dc8f252f1a4d1160e76b498f0"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2023, ARS Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) announced its financial results for the three and nine months ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#x2019;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;"></td>
     <td style="width:90%;"></td>
    </tr>
    <tr style="height:10pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7%;"></td>
     <td style="width:4.02%;"></td>
     <td style="width:88.98%;"></td>
    </tr>
    <tr>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10.1pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Press Release dated November 9, 2023</span></a></p></td>
    </tr>
    <tr style="height:10.1pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:22%;"></td>
     <td style="width:29.76%;"></td>
     <td style="width:4%;"></td>
     <td style="width:44.24%;"></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: November 9, 2023</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Richard Lowenthal</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Richard Lowenthal, M.S., MBA</span></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <hr style="page-break-after:always;" /></div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>spry-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;width:6.5in;;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img41264513_0.jpg" alt="img41264513_0.jpg" style="width:168px;height:65px;">&#160;</p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Resubmission of New Drug Application (NDA) for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> anticipated in H1 2024</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ended third quarter with $241.9 million in cash, cash equivalents and short-term investments with an expected operating runway of at least three years; well-capitalized to support anticipated H2 2024 launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in the U.S.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SAN DIEGO -- November 9, 2023 </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the third quarter of 2023.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;While we remain disappointed in the FDA&#x2019;s decision to change the repeat-dose rhinitis study from a post-marketing requirement to a pre-approval requirement, we</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">are moving quickly to complete the study and meet the urgent medical need for people with severe allergic reactions. We continue to expect resubmission of our New Drug Application for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the first half of next year, with a U.S. launch anticipated in the second half of next year, if approved. We are incredibly appreciative of the outpouring of support we have received from patients and caregivers following the delay as they eagerly await the approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Mr. Lowenthal continued: &#x201c;During our Type A meeting with the FDA in October, the agency reinforced that the completion of our repeat-dose rhinitis study for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> will sufficiently address the agency&#x2019;s outstanding questions. Further bolstering our confidence in the study&#x2019;s prospects, we were pleased to announce the publication of positive results from the single and repeat dose clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Allergy and Clinical Immunology</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, which add to the growing body of clinical evidence for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and underscore its potential to be a safe and efficacious treatment option. ARS Pharma remains well capitalized to fund our operations for at least the next three years with anticipated cash and equivalents of approximately $195 million expected at the time of the anticipated </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">launch in the second half of 2024.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
   <hr style="page-break-after:always;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Regulatory Status of neffy&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(epinephrine nasal spray)</font></p><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In September, ARS Pharma announced that the FDA issued a Complete Response Letter (CRL) regarding its NDA for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the CRL, the FDA requested completion of a pharmacokinetic/pharmacodynamic study assessing repeat doses of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> compared to repeat doses of an epinephrine injection product under allergen-induced allergic rhinitis conditions to support approval.</font></div></div><div style="margin-left:0.6798611111111111in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.846483733708581%;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No member of the May 2023 FDA Advisory Committee (PADAC), that concluded a favorable benefit-risk profile of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(16:6 for adults and 17:5 for children), requested a repeat dose study during allergen-induced allergic rhinitis, and ARS Pharma aligned with FDA in August 2023 that such a study could be completed as a post-marketing requirement.</font></div></div><div style="margin-left:0.6798611111111111in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.846483733708581%;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma expects to report its findings from this study in the first quarter of 2024. With this study being previously planned as a post-marketing requirement, ARS Pharma was able to quickly ramp up following the CRL.</font></div></div><div style="margin-left:0.6798611111111111in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.846483733708581%;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The company anticipates a resubmission of its NDA in the first half of 2024, positioning ARS Pharma for an anticipated FDA action date and potential launch in the second half of 2024.</font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In October, ARS Pharma announced its participation in a Type A meeting with the FDA to understand the agency&#x2019;s view related to the CRL, and to confirm next steps to support an NDA resubmission seeking approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><div style="margin-left:0.6798611111111111in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.846483733708581%;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At this Type A meeting, the FDA confirmed that the previously agreed upon design for the repeat-dose study to evaluate the similarity of twice dosing injection and twice dosing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> under allergen-induced allergic rhinitis will generate the necessary data to answer its outstanding questions regarding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div><div style="margin-left:0.6798611111111111in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.846483733708581%;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> NDA re-submission will be classified as Class 2, with an action expected within six months of submission.</font></div></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Business Updates and Anticipated Milestones</font></p><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Marketing authorization application (MAA) for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is under review by the European Medicines Agency (EMA) with a decision now expected in the second quarter of 2024. Submissions to other regulatory authorities in additional countries are planned for 2024.</font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In October, ARS Pharma announced that results from the single and repeat dose clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were published in the </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Allergy and Clinical Immunology (JACI)</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The clinical study evaluated single and repeat doses of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">compared to single and repeat doses of approved injection products in healthy subjects.</font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In November, ARS Pharma will present positive results during the 2023 American College of Allergy, Asthma and Immunology (ACAAI) meeting supporting that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is expected to be a safe and effective treatment option in sub-populations including upper respiratory tract infection, pediatrics &#x2265;30 kg and patients with varying body mass index (BMI) or body weight.</font></div></div>
   <hr style="page-break-after:always;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Following the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> program delay, ARS Pharma implemented a plan to prioritize resources on clinical and regulatory activities while maintaining core commercial readiness status ahead of the anticipated FDA approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in H2 2024. </font></div></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Quarter 2023 Financial Results</font></p><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Position: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and short-term investments were $241.9 million as of September 30, 2023, which ARS Pharma believes is sufficient to fund its current operating plan for at least three years.</font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research and development (R&amp;D) expenses were $3.0 million for the quarter ended September 30, 2023. </font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">G&amp;A Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General and administrative (G&amp;A) expenses were $15.0 million for the quarter ended September 30, 2023. </font></div></div><div style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5235502658900995%;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $14.9 million for the quarter ended September 30, 2023. <br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></div></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Type I Allergic Reactions including Anaphylaxis</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.3 million currently have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ARS Pharmaceuticals, Inc.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">www.ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statements in this press release that are not purely historical in nature are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, ARS Pharma&#x2019;s plan to complete the repeat-dose study under allergen-induced allergic rhinitis conditions and file its NDA re-submission to the FDA in the first half of 2024, with an anticipated launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved, in the second half of 2024; ARS Pharma&#x2019;s expectation to report topline data from its repeat-dose study in the first quarter of 2024; ARS Pharma&#x2019;s projected cash runway; ARS Pharma&#x2019;s belief that it is well capitalized to support the launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., if approved; whether the repeat-dose study under</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
   <hr style="page-break-after:always;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">allergen-induced allergic rhinitis conditions will sufficiently address the FDA&#x2019;s outstanding questions; the potential for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to be a safe and efficacious treatment option; the classification of the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">re-submission, anticipated timing for regulatory review decisions on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and the potential approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the timing of the EMA&#x2019;s decision of ARS Pharma&#x2019;s MAA and submissions to other foreign regulatory authorities; and</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#x201c;anticipate,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;expects,&#x201d; &#x201c;on track to,&#x201d; &#x201c;will,&#x201d; &#x201c;potential&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma&#x2019;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the ability to obtain and maintain regulatory approval for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the ability to successfully complete the repeat-dose study under allergen-induced allergic rhinitis conditions within the anticipated timeframe, as a result of challenges inherent to enrolling, conducting and completing clinical trials; even though the FDA has stated that completion of the repeat-dose study under allergen-induced allergic rhinitis conditions for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> will sufficiently address the agency&#x2019;s outstanding questions, there is no guarantee that new issues will not be identified which could delay or prevent the approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the labelling for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved; the scope, progress and expansion of developing and commercializing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-&agrave;-vis intramuscular injectable products; ARS Pharma&#x2019;s ability to protect its intellectual property position; uncertainties related to capital requirements; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#x201c;Risk Factors&#x201d; in ARS Pharma&#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on August 10, 2023, and in ARS Pharma&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, being filed with the SEC today. This document can also be accessed on ARS Pharma&#x2019;s web page at </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ir.ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> by clicking on the link &#x201c;Financials &amp; Filings.&#x201d;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma Investor Contacts:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Justin Chakma</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">justinc@ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma Media Contact:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sherry Korczynski</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">sherryk@ars-pharma.com</font></p>
   <hr style="page-break-after:always;"></div>
  <div class="section-group" style="margin:auto;width:7.5in;;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and par value data)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.999%;"></td>
     <td style="width:1.602%;"></td>
     <td style="width:1.602%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.597000000000001%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.602%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.597000000000001%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60,532</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">210,518</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">181,370</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63,863</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,564</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,319</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">244,466</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">277,700</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use asset</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">300</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">445</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets, net</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">617</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">329</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other assets</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,173</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,961</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total assets</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">248,556</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">281,435</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liabilities, convertible preferred stock and stockholders&#x2019; equity</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable and accrued liabilities (including related party amounts of $208 and $16, respectively)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,945</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,931</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease liability, current</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">235</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">230</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contract liability, current</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">283</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,180</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,444</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease liability, net of current portion</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">251</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contract liability, net of current portion</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,854</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,272</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,549</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and contingencies</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at September 30, 2023 and December 31, 2022; 95,796,254 and 93,943,316 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">361,571</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">349,408</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive (loss) gain, net</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(161</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">407</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(124,135</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(76,938</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">237,284</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">272,886</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities, convertible preferred stock and stockholders&#x2019; equity</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">248,556</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">281,435</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <hr style="page-break-after:always;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.431%;"></td>
     <td style="width:1.008%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.089%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.008%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.089%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.008%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.089%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.008%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.27%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue under collaboration agreements</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">189</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,316</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development (including related party amounts of $307, $776, $1,382 and $1,888, respectively)</font></p></td>
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,002</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,893</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16,862</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13,666</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative (including related party amounts of $322, $73, $840 and $344, respectively)</font></p></td>
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14,976</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,926</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40,462</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,723</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17,978</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,819</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57,324</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21,389</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(17,978</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6,630</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(57,294</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(20,073</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net</font></p></td>
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,112</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,097</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(180</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(14,866</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6,583</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(47,197</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(20,253</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(568</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(14,847</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6,583</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(47,765</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(20,253</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(0.16</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(0.21</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(0.50</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(0.66</font></p></td>
     <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;">
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95,576,627</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30,755,123</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94,910,012</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30,578,516</font></p></td>
     <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img41264513_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img41264513_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8$)_4FOHL^C&CAJ=*"LK_DCYO()2K8JI5F[NV_S/1J***^'/O HHHH ****
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M_H?7<-1_BR]/U%HHHKXP^V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[5;P_+J>MD.*]CB?9/:?Y]#]$J***_/#]'"BBB@ HHHH **** "OG;_ (*
M?\FG^-OK9?\ I9#7T37SM_P4 _Y-/\;?6R_]+(:[L#_O5+_$OS.#'_[I5_PO
M\C\>J***_63\A/<OV3_VG)OV9?%VJZBVBC7=-U:W2WNK=9O)E38Q9'1B",C<
MP*D<YZC%?<GA_P#X*;?"358T_M&W\0:'-_$MQ8B51]&B=L_E7YG^!?AEXL^)
MUY=6GA/P]?\ B"YM8Q+/'8Q;S$I. 6],GIZX-=;)^RQ\88?O?#3Q*?\ =L&;
M^5>%C,#@<14<JTK2];'OX+'8_#TU&C&\?2Y^E*_\%#O@8T>[_A*KH'^Z=)NL
M_P#HNN3\9_\ !3;X6:'82MH%IK/B:_Q^ZB2U^RQ$_P"U))@@?16^E?GK<?LX
M?%BU!,OPU\5*!UQI$Y_DM>?75K/874UK<PR6US"YCE@F0H\; X*LIY!![&N2
MGDF!D[QDY?-?HCJJ9YCXJTHJ/R?ZL]-^/G[1GB[]HCQ(FI>([A8+&V+"QTBU
MR+:T4]< \LY&,N>3[#BN]_9)_8ZU;]HK4AK&I2OI/@2SF\NYO(R/.NG7!,,(
M['D9<C SQD\#YPKZ _8]_:?N_P!G7QYLOY);CP5JSK'JEJN6,)Z+<HO]Y>X'
MWEXZA<>MB:=2CA7#!JS6W_ \SR<+5IUL4IXQW3W_ .#Y'ZY^#_!^C> ?#=AH
M'A_3H=*TBQC$4%K N%0>ON2<DD\DDD\UMU4TO5+36M-M=0L+F.\LKJ)9H+B%
M@R21L,JRD=000:MU^5R;;;EN?K$4DDH[!1112*"BBB@ HHHH **** "BBB@
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MY(O5W;;/@,7URJ@"YF  P )6&/UI?[0NO^?J?_OZW^-?L[_PQA\$O^B<Z/\
M]\O_ /%4?\,8?!+_ *)SH_\ WR__ ,57A_ZP8?\ D?X?YGN_ZN8C^=?C_D?C
M%_:%U_S]3_\ ?UO\:/[0NO\ GZG_ ._K?XU^SO\ PQA\$O\ HG.C_P#?+_\
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M[CAW%7C+#2Z:K]3UBBBBOCS[0**** "BBB@ KYS_ ."@K;?V4/&(_O260_\
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M/Z5\;5^L9?4=7"TYRWL?D684U2Q=2$=KL[[]GY7D^//PX$8R_P#PD>GX_P#
MA*_="OQF_8?\)OXN_:@\$1*NZ+3[B34Y3_=6&-F4_P#?>P?C7[,5\CQ#-.O"
M/9?J?8<.0:H3GW?Y?\.+1117RI]:%%%% !1110 4444 %%%% !1110 4444
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M^6VTNQERQ[#?($4#\:_/?]IK]JCQ)^TIX@A>]3^R/#5DY:PT6&0NJ,>/-D;
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M_#O31_NR3#^3U$?V'/@8W_-/;'\+FX'_ +4KW?\ 6'#_ ,DOP_S/!_U<Q/\
M/'\?\C\L_@'^T!XG_9Y\9#7/#TJSVTX6/4-+N"?(O(P<@-C[K#)VN.02>H)!
M_1KP'_P4>^$'BFQA;6;V^\)7[#]Y;ZA:22HK>TL08$>Y"_05V!_87^!9_P":
M?68^EY=?_':9_P ,*? OK_PK^U_\#;K_ ..UY6+QV78Q\U2$E+NK?YGJX/ Y
ME@5R4YQ<>SO_ )'4>#?VHOA3\0->M-$\/^.-+U'5KLE;>S5F224@$D*&49.
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MZVWK<H/R3_Z]>R5_2'"JMDU#T?\ Z4SMI_"@HHHKZLT"BBDH 6BBB@ HHHH
M**** "BDS2T %%%% !1110 44E+0 4444 %%%% !1124 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFU7%U<1A\1\3?.D^SW7HM+>IC3E>Z9T%%%%?I9N%%%% !1110 4444 %%%%
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MKB_^%R>#?^@W'_WZD_\ B:/^%R>#?^@W'_WZD_\ B:]O^ULN_P"@B'_@4?\
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MOQ]U9+'P(UJ6 EO9TC5>Y"G>Q_\ '1^=?<9Y.$,LQ#GMR2_%67XFL_A9YC\
M[5Y_B%'(H^6&UE=OQPH_4U],5Y3\ O![Z/H<VL7,>RXU''E*PP5A'0_\".3]
M *]6KR>$\'/!Y7#VBLYMRMZ[?@DQ4U:(4445]D:'D'[2%WY?AW2K?/\ K+LN
M?^ H?_BJ\@\7>%)/#/\ 93MN:#4+**Z1CV8J-Z_@3^1%>C?M+76Z\T.U!^[%
M-)CZE0/Y&NM^)O@S^V_AK;+"FZ\TN!)HL#DA4 =?Q4?F!7XYG.7O-L=F#AK*
ME&%ONNU\U?YV.:4>9LU/A'XN_P"$M\'V[3/NOK/_ $>XYY) ^5OQ&#]<UV]?
M+OP9\7?\(OXOACE?;8ZABWEST5B?D;\"<?1C7U%7VW#&:?VGE\7-WG#W7\MG
M\U^-S6G+FB%%%%?6FAR?Q.\5CP?X1O+M&VW<@\BV'?S&R ?P&3^%?.VK^#WT
MGP'H^M3AOM&H7+XW'I%M^7\20Q_$5WOQ$GD^)7Q0L/#-LY-C9-MF9>@/65OP
M "CWKHOC_I\47@&R$2!([6[C5%7HJ[&4#^5?DV=4WG"QF*_Y=T(\L?.5TYOY
M;'/+WKOL5_V;[KS/#NK6V?\ 578?_OI!_P#$FO7J\)_9MN]M]KMKG[T<4H'T
M+#^HKW:OK.%:GM,GH/M=?=)HTI_"@HHHKZTT"O%?CYJDNK:GHGA:T;=-<2++
M(H_O,=D8/YL?RKVAF"*68X4#))[5X-\/V/Q ^,6H:ZXWVMGNEBW=,?<B'Y9;
M\*^/XDJ.K2I9=!^]7DE_VZM9/[C.?2/<V/CEX.BM_!>E7-HF!I.V X'_ "R(
M"\_\""_F:SOV<_$GESZCH4K\./M4 )[C"N!_XZ?P->Q^(-(BU[1+[3IAF.ZA
M:(^V1P?P.#^%?)_AO5;CP3XOM;N0%);&XV3ITRH)60?EFOEL\2R3.\/F,%:$
MM)?+1_\ DK5O0SE[LE(^P:*9#*D\22QL'C=0RL.A!Y!I]?K"=]4= 4444P"B
MBB@ HHHH **** "BBB@ HHHH **** "OSA_;^_:_&O3WOPN\%7V=-B8Q:[J5
MN_%PX/-JC#^ '[Y'4C;T#9]+_;S_ &P/^%<Z;<_#SP;>X\5WD6W4K^!N=-A8
M?<4CI,X/U53GJ5K\Q/I7V.399S6Q59>B_7_+[SXK.LTY;X6B_5_I_G]P4445
M]L?#A1110 4444 =-\.OB1XB^$_BNV\2>%M0_LS6+<,L=QY*2C:PPRE7!!!'
M!K[>^$G_  5)*^39?$CPSGHK:MH/\W@<_F5?Z+7Y]T5P8G X?%_Q8Z]^IZ&%
MQ^(P?\*6G;H?NE\,_CIX#^,5F)_"/B>QU=PNY[5)-ES'_OPMAU_$8KO*_GXL
M;VXTR\AN[.XFL[N%MT=Q;R&.1#ZJP((/TKZ8^$O_  4,^*?PW\FTUBZA\;Z2
MF!Y.KY%R%_V;A?F)]W#U\KB>'YQ][#ROY/?[_P#ACZS"\14Y>[B(V?=;?=_P
MY^M]%?,?PE_X*#?"OXE&&TU._D\%ZO)@?9]:PL#-Z+<#Y,?[VT^U?2MI>0:A
M;17%K-'<V\B[HYH7#(X/<$<$5\Q6P]7#RY:L6CZFCB*6(CS4I)HGHHHK Z"K
MJ&F6FJ0F*\M8;N+^Y-&''Y&N'UKX&>%M6W-#;2Z9*?XK20A?^^3D5Z%17GXK
M+\)C5;$TE+U7Z[B:3W/G[6_V==4M=SZ7J5O?+VCN%,3_ )C(_E7 ZUX#\0^'
M=QO](N8HUZRHGF)_WTN17U_17QF+X(RZO=T&Z;^]?<]?Q,G2CT/B'<#17U[K
M?@'P]XBR;_2;:60_\M538_\ WTN#7 ZU^SGIEQN?2]2N+%^T<X$J?GP?U-?%
M8O@C,:-W0DJB^Y_<]/Q,G2ET/ **] UKX'^*=)W-#;1:G$/XK63YO^^6P?RS
M7$7^G7>ES&&]M9K.0?P3QE#^M?&8K+\7@G;$TG'U6GW[&;36Y6HHHKSR0HHH
MH ^F/@&NWX=P'^]<3'_Q[']*]&K@/@6NWX;Z>?[TDQ_\B-7?U_3^1KERO#+^
MY'\D=\?A04445[A04444 ?,OQZ_Y*+/_ ->T/\C7K7PNU :7\)])N3;W%T$1
M_P!U:QF21OWK#A1UKR7X]?\ )19_^O:'^1KV7X-G_BVNB?[DG_HQJ_)\D3?$
M>-479VE_Z4CGC\;"Z\>ZE,NS2O"6KW4[< WB+;1CZECG]*Y^/X7ZOXTUB/5/
M&MY&T4?^JTJS8^6@]"W\\<GUKU6BOO*V5QQ;7URHZD5KRZ*/S2U?HVUY&W+?
M<BMK:*SMXX(8UBAC4*D:#"J!T %2T45[:2BK(H*^<_VBO^1VL_\ KQ7_ -#>
MOHROG3]HG_D=;/\ Z\4_]#>OAN-/^13+_%'\S*K\)TGP:\!^'_$7@M+S4=+@
MN[DW$B&20'. 1@=:[K_A4_A#_H VOY'_ !K$^ '_ "3U/^OJ;^8KTBNW(\OP
M=3+,/.=&+;C&[<5V]!Q2Y4<E_P *G\(?] &U_(_XT?\ "I_"'_0!M?R/^-=;
M17M_V9@?^?$/_ 5_D7RKL<E_PJ?PA_T ;7\C_C7SM\3-+M-%\=:K964"VUK$
MZ!(DZ+E%)Q^)-?6U?*?QA_Y*1K7^_'_Z+2OSWC;!X;#X"G*C3C%\ZV27V9=C
M"JDEH?0?PO\ ^2>Z!_UZ)_*NIKEOA=_R3WP__P!>B5U-?H>6_P"Y4/\ !'\D
M;QV04450US5HM!T>]U&<XBMHFE;WP,X_'^M=TYQIQ<Y.R6HSPKXK79\<?%#3
M] BD_P!'MW2V8YX#,0TA_!<#\*]\AEMK>%(HY(UC10JJ&& !T%?.'PT\!CXH
M:EK%_JMQ/#$K[V>$@,\KDL1D@\ ?S%>@?\,YZ!_T$-2_[[3_ .(K\TR2MF-1
MU\RHX=35:5TW/E]U:)6L]C"/-J[;G:^-M)M_%'A74M-\V,R31'R_F'$@Y4_F
M!7S'X$\0-X4\7:=J+$I''+Y<X_Z9M\K?EG/X5[/_ ,,YZ!_T$=2_[[3_ .)K
MR+XE>"QX'\3/I\;R36DD:RP22XW,IX(./0@_I7C\41S",Z.9U*"INFTKJ7-U
MNKZ*UG?[R:E])6/K)6#J&4Y!&013JX?X.^)O^$D\#V?F/NNK/_19<GGY0-I_
M%=OZUW%?K6#Q4,;AX8BGM))_>="=U<****[!GQEJTGD^)+Z3&=E[(V/7$A-?
M0FF_'[PG>1J9Y[BQD(Y2:$M@_5<U\_:D WBBZ!&0;]P0?^NIKZV/A;16ZZ18
M'ZVR?X5^+\)T\=*KB7@ZD8I-74HMW^*VS5CEIWN[')WOQT\(6L+/%?R7C@<1
MP0/D_F /UKC] L9_CAXH.LZF%@T#3F\N*P#Y9SP<-CUX)/?H.YKMO'GPMTOQ
M-H,T-C96MAJ$?[RWFAB6/+#^%L#D'I[=:\%\%>+;_P"''B9I7BD"JWD7MFW!
M8 \C_>!Z?_7KTLYQF+PV-H4<XM+#-W]U-)M?S7;;L[.U]?/8J3::YMCZR5%C
M5550JJ,!5& !Z4ZJFE:I;:UI]O?6<JSVLZ!XY%[@_P!:MU^IPE&45*+NF= 4
M4458'SM\>)O[0^(VG6@YV00QX]VD;_$5]#[1LVX^7&,5\Y>-&_M;X[PP]0M[
M:P_D$)_K7T=7PG#S]KCLPK=YV_\  ;HRAO)GR9\3/"I\'^,+RS12MI(?M%L?
M]ACT'^Z<C\*^@_A7XN'C#PA:SRONO;?_ $>Y]=RC[WXC!_$UB?';PB==\+?V
ME!'NO--)DX'+1'[X_#AOP->7_!/Q=_PC?BY+69]MCJ6('R>%D_@;\R1_P*OF
MJ#_U;X@=%Z4:VW97>GW/3T=S-?NYVZ,^G*Y_QUXFC\(^%[[4VP98TVPJ?XI#
MPH_/GZ UT%>&_%R^G\<>.M*\(6#GRXG!G9>@=ADD_P"ZF3_P*OT+.\=+ 8.4
MJ6M27NP7>3T7W;_(VD[(UO@!X8D@TV\\17F7NM08K&[]3&#EF_X$V?\ OD5O
M_'"U^T?#C46QGRGBD_*11_6NTT^P@TNQM[.V3R[>"-8XU'90,"N?^*%M]J^'
MNO1]3]E9_P#OGYOZ5QRRV."R.I@HZM0E?S;3N_FQ<MHV/&OV>;KR/'%Q#G_7
MV3C\0RG_ !KZ.KY8^"UU]E^)&E9.!*)(OS1OZ@5]3UY'!%7GRMQ_EDU^"?ZD
MTOA"BBBOT$V.)^,'B+_A'? M\T;[;B['V6+'7+<,?P7<:P?@#H\6D^#Y+Z1D
M2;4)BXRPR(U^51^>X_C7)_'35)?$?C32_#MH=Y@VJ5'_ #VE(Q^2X_,UTZ_L
MYZ%M&[4=1+8Y(9 /_0:_-I5L7C,\J8C"TE4C07(KRY5S/=[/7=&-VY770]4^
MU0_\]H_^^A7S/\<-#32?'$US"5,&H(+@;3G#_=<?F ?^!5Z-_P ,YZ!_T$-2
M_P"^T_\ B*YOX@_!"Q\,^%[K5-,NKNXEMB'DCG92#'G#$84<C.?P-9\1TLRS
M' 2C5PJBH>]=3NU;?3E5]+BGS26QW7P1\2?V]X)@@D?=<Z>?LSY/.T<H?^^<
M#\#7H-?-/P)\2?V+XR%C(^VWU)/)Y/'F#E#_ .A#\:^E:^@X7S#Z_EE-R=Y0
M]U_+;\+%TY7B+1117UIH%%%% !1110 4444 %%%% !1110 5\V_ME?M86?[/
M?A/^S-(DBNO'6J1'[#;G#"TC.0;F0>@.0JG[S#T#5VW[2O[1.B?LY^ 9=:O]
MMYK%UNATK2]V&NIL=3W$:Y!9NPP.I /XU^.O'&M_$KQ;J?B7Q%>MJ&KZA*99
MIFX [!5'\*J, *.@ %?1Y3EOUJ7MJJ]Q?C_P._W'S.<9HL)'V-)^^_P_X/8R
MM2U*[UC4+J_O[F6\OKJ5IY[F=BSRR,269B>I))/XU6HHK]$2ML?G&^K"BBB@
M HHHH **** "BBB@ HHHH .M=_\ "_X]>/\ X-W*R>$?$]]I<&[<UCO\VU?_
M 'H7RGX@ ^]<!143IQJ1Y9JZ\RX5)TY<T'9^1^AGPE_X*E02>39?$?PTT#<*
M=6T++)]6@<Y'_ 6/TK[+^&WQJ\#_ !>L!=>$?$MAK2[=SP0R;9X_]^)L.OX@
M5^%%6-.U&[T>^AO;"ZGL;V%MT5S:RM'*A]592"#]*^=Q.18>KK2?*_O1])AL
M_P 11LJRYU]S/Z!:6OR7^$O_  45^*'P]\FUUZ6#QUI2X!34SY=TH_V9U&2?
M=U:OM3X2_M_?"GXGF"TO-3?P=K$F!]DUS$<9;T6<'RS_ ,"*D^E?*XG*<5AM
M7'F7=:_\$^LPV;X3$Z*7*^ST_P" ?2E%0V]Q#=PQS02I-#( R21L&5@>A!'4
M5-7CGM!1110 5!>6-MJ$)BNK>*YB/5)D#+^1J>BIE%25FM .!UKX(^%=8W,E
MDVG2G^.S<H/^^3E?TK@=:_9ROX-SZ5JD-TO:.Z0QM]-PR/T%>^45\UB^&LJQ
MEW.BD^\?=_+3[T9NG%]#Y%UKX=^)/#^YKW2+@1KUEA7S4_-<_K7.=R.XZBOM
MVL/6O!.@^(@?[0TJVN7/_+0H%?\ [Z'/ZU\7B^ X[X2M\I+]5_D9NCV9A?!1
M=OPUTGW\T_\ D1J[FL[0=#M/#>DP:;8HT=K!D(K,6(R2>I]R:T:_3,OH2PN$
MHT)[QC%/U22-XJR2"BBBN\84444 ?,GQX.?B-<_]>T/\C7LOP9/_ !;71?\
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MM6BC+,GI93%T\-4ER-WL[-7^Z_XBC%1V"FR1K*C(RAD88*GH1Z4ZBO>+/,?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>spry-20231109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-07T18:52:42.3713+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="spry-20231109.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>spry-20231109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-07T18:52:42.8449+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>spry-20231109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-07T18:52:42.4472+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ars-pharma.com/20231109" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:spry="http://ars-pharma.com/20231109" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="spry-20231109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="spry-20231109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140615858509232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11682 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">771-9307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>spry-20231109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="spry-20231109.xsd" xlink:type="simple"/>
    <context id="C_23ea1e35-ca75-448c-ab99-c9d712614066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2023-11-09</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_6ce41ec3-341a-4133-9148-9736b3fc89bb">0001671858</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_fec97013-e028-45f1-bc64-fefbf96007cc">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_164e4ecb-3525-4392-ad92-ff5d02015bd3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_d7da6f05-f290-4a88-8239-ea7b8572011c">2023-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_af8f3e62-b507-48eb-b70a-546ae3e3ff1c">ARS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_8f7f72c2-f4f5-4064-9179-5d7563853b74">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_351af373-8aa4-4516-bd3e-6c481c791138">001-39756</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_466685db-f4a3-4340-a2de-a446922ef9ba">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_ebb00231-8e9f-45da-89e4-48c5aa314c22">11682 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_940a3ff8-21f2-436e-a998-040c67495f30">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_7b1773ab-554f-4a2c-987f-77fc832c395a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_825e39f6-ea30-4f85-acfe-94e749952516">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_c09c5d35-b152-4f78-bf76-45a0aad07bdd">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_082f02ce-61fb-47be-b9cb-9c4230b47a7e">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_0796cfa9-38a6-4f1b-8308-02cd81a5c635">771-9307</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_2cee1272-84fd-4e5f-899d-b7bb12aa2e68">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_a5374b6f-7177-49ff-be59-bad338c87652">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_b8f2dc52-556f-4412-93e7-c8d9bfdca2ed">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_53696489-e094-40f9-95bb-c8a766776983">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_723adde6-a204-4baf-8fdd-ef4cb49b1f43">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_a4d6a0df-9de5-407e-b4e5-43dfc26c7e78">SPRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_04282263-27c8-4bb7-b499-4dcf197b5788">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_e6db4548-af57-4f25-a393-24e8be206221">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_23ea1e35-ca75-448c-ab99-c9d712614066"
      id="F_778c3e0a-e679-463d-b940-2e4e1867794f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;%!+ 0(4 Q0    ( $V :5?#-RK#[0   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $V :5>97)PC$ 8  )PG
M   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ 38!I5TNJ=6*%!   T!$  !@              ("!# @  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $V :5>?H!OPL0(  .(,
M   -              "  <<,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M38!I5Y>*NQS     $P(   L              ( !HP\  %]R96QS+RYR96QS
M4$L! A0#%     @ 38!I5QPX9>H_ 0  / (   \              ( !C!
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $V :5<D'INBK0   /@!   :
M              "  ?@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( $V :5=ED'F2&0$  ,\#   3              "  =T2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "<4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="spry-20231109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="spry-20231109.htm">spry-20231109.htm</File>
    <File>spry-20231109.xsd</File>
    <File>spry-20231109_lab.xml</File>
    <File>spry-20231109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "spry-20231109.htm": {
   "nsprefix": "spry",
   "nsuri": "http://ars-pharma.com/20231109",
   "dts": {
    "inline": {
     "local": [
      "spry-20231109.htm"
     ]
    },
    "schema": {
     "local": [
      "spry-20231109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "spry-20231109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "spry-20231109_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_23ea1e35-ca75-448c-ab99-c9d712614066",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20231109.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_23ea1e35-ca75-448c-ab99-c9d712614066",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20231109.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ars-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-061989-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-061989-xbrl.zip
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MM'PL+BT7&RZ+#"+-*[;OZ_O:@CIO91,5E1LWE8NLHGOOS[726D,ZS.OL^?O
MLGGR@)PMV:!_]SCS7P9PD0#YO4<*"^DI*9I@<<\P#8>RP+2I$6@F9;J+D&R
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MY4,:P]4Q \JI1"QX !XS1I!SQ4(]XCXM;P?*1J%EH] &A?^!2HPP]"<R5RT
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M+3(P,C,Q,3 Y+FAT;5!+ 0(4 Q0    ( $V :5?>Q;RT$@,  *,)   1
M          "  605  !S<')Y+3(P,C,Q,3 Y+GAS9%!+ 0(4 Q0    ( $V
M:5>$%MP/D08   1)   5              "  :48  !S<')Y+3(P,C,Q,3 Y
M7VQA8BYX;6Q02P$"% ,4    " !-@&E7)T40>+X$   C+0  %0
M    @ %I'P  <W!R>2TR,#(S,3$P.5]P<F4N>&UL4$L! A0#%     @ 38!I
M5VR'ZQC,*   M,H#  \              ( !6B0  '-P<GDM97@Y.5\Q+FAT
7;5!+!08     !0 % $$!  !330     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
